Peripheral arterial disease (PAD) of lower extremity and dyslipidemia
Authors:
Denisa Čelovská; Viera Štvrtinová; Andrej Dukát
Authors place of work:
II. interná klinika LF UK a UN Bratislava
Published in the journal:
AtheroRev 2016; 1(3): 138-143
Category:
Reviews
Summary
Peripheral arterial disease (PAD) of lower extremity is predominantly a manifestation of atherothrombotic process. Effective cardiovascular (CV) risk treatment is underestimated in clinical practice despite significantly increased cardio-cerbrovascular mortality and morbidity in symptomatic and even in asymptomatic PAD patients. Atherogenic dyslipidemia is a significant risk factor for vascular risk stratification in PAD patients. PAD patients have very high CV risk and the goal level of LDL cholesterol is less than 1.8 mmol/l or even lower according to new studies. First line therapy in PAD patients is statin treatment. However, in not reaching the LDL-cholesterol goal level conveniently, ezitimibe is added. PCSK9 inhibitors are a new perspective in high risk patients and in statin intolerance. What cannot be forgotten is modification of life-style especially in reduction of remnant lipoproteins, which play an important role in peripheral circulation.
Key words:
peripheral arterial disease of lower extremity – dyslipidemia – cardiovascular risk
Zdroje
1. Štvrtinová V, Štvrtina S. Ischemická bolesť pri periférnom artériovom ochorení končatín. In: Štvrtinová V et al. Bolesť končatín. SAP: Bratislava 2012: 111–132. ISBN 978–80–896027–05–1.
2. Murabito JM, Evans JC, Nieto K et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143(6): 961–965.
3. Fowkes GF, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329–1340. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(13)61249–0>.
4. Štvrtinová V, Štvrtina S, Wsólová L et al. Prevalence of peripheral arterial disease in the Slovak Republic. CEVJ 2009; 8(1): 32.
5. Criqui MH, Ninomiya J. The epidemiology of peripheral arterial disease. In: Creager M, Dzau VJ, Loscalzo J (eds). Vascular Medicine. 1st ed. Saunders Elsevier: Philadelphia 2006: 223–238.
6. Norgren L, Hiatt WR, Dormandy et al. [TASC II Working Group]. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45(Suppl): S5-S67.
7. Clement DL, Boccalon H, Dormandy J et al. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol 2000; 19(2): 97–125.
8. Alberts MJ, Bhatt DL, Mas JL et al. Three year follow up and event rates in the international Reduction of Atherotrombosis for continued Health registry (REACH). Eur Heart J 2009; 30(19): 2318–2326. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp355>.
9. Bhatt D, Steg P, Ohman F et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherosclerosis. [REACH registry Investigators]. JAMA 2006; 295(2): 180–189.
10. Češka R, Kvasilová M, Procházková R et al. Hyperlipoproteinémie a dyslipoproteinémie I. Klasifikace, diagnostika, kardiovaskulární, kardiometabolické a reziduálne riziko. Vnitř. Lék 2010; 56(6): 526–531.
11. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. vyd. Vydavateľstvo UK: Bratislava: 2001. ISBN 80–223–1608–3.
12. Ridker PM, Stampfer M, Rifai N. Novel Risk factors for systematic Atherosclerosis. JAMA 2001; 285(19): 2481–2485.
13. Vrablík M. Hypertriglyceridemický pás a kardiovaskulárni riziko. Interní Medicína pro praxi 2007; 9(12): 552–554. Dostupné z WWW: <http://www.internimedicina.cz/pdfs/int/2007/12/04.pdf>.
14. [Heart Protection Study Collaborative Group]. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22.
15. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108(12): 1481–1486.
16. Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patinets with peripheral vascular disease. Am J Med 2003; 114(5): 359–364.
17. Štvrtinová V, Šefránek V, Murín J et al. Odporúčania pre diagnostiku a liečbu periférneho artériového ochorenia dolných končatín PAO DK. Vask Med 2010; 2 (52 Suppl): 3–18.
18. Gašpar Ľ, Komorníková A, Gavorník P et al. Liečba kritickej končatinovej ischémie prostaglandínom E1. Vaskulárna medicína 2015; 7(2): 86–88.
19. Nguyen CD, Andersson Ch, Jensen TD et al. Statins treatment and risk of reccurent venous thromboembolism a nationwide cohort study. BMJ Open 2013; 3(11): e 003135. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2013–003135>.
20. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology(ESC). Eur Heart J 2011; 32(22): 2851–2906. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr211>.
21. Baigent C, Keech A, Kearney PM, et al. Cholesterol treatment Trialists‘ (CTT) Collaborators: Efficacy and safety of cholesterol – lowering tratment: prospective study meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 2005;366(9493): 1267–1278. Erratum in Lancet 2005; 366(9494):1358. Lancet 2008; 371(9630): 2084.
22. Dukát A. Reziduálne kardiovaskulárne riziko – závažný problém, ktorý si bude vyžadovať nové liečebné prístupy. Cardiology Lett 2008; 17(6): 229–233.
23. Češka R, Votavová L, Aleksičová T. Přelom v léčbe hypercholesterolemie – inhibitory PCSK9. Co zatím víme o alirokumabu (přípravku Praluent). AtheroRev 2016; 1(1): 34–41.
24. Sudhop T, Lütjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption bx ezetimibe in humnas. Circulation 2002; 106(15): 1943–1948.
25. Cannon ChP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therpay after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
26. Murín J, Pernický M, Kiňová S. Nové liečebné postupy k dyslipidémii. Cardiology Lett 2014; 23: 197–206.
27. Kumbhani DJ, Steg PG, Cannon CP et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35(41): 2864 -2872. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu080>.
28. Rajamani K, Colman PG, Li LP et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecifi ed analysis of a randomised controlled trial. Lancet 2009; 373(9677): 1780–1788.
29. Wang T, Elam MB, Forbes WP et al. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003; 171(2): 337–342.
30. Vrablík M. Zítřky lipidy modifikující terapie – jaké budou? Kardiol Rev 2012; 14(3): 172–175.
31. Vrablík M, Češka R. Novinky v oblasti hypolipidemické léčby. Vnitř Lék 2014; 60(11): 949–957.
32. Robinson JG, Farnier M, Krempf M et al. Efficacy and Safety of Alirocumab in reducing Lipids and cardiovascular Events. N Engl J Med 2015; 372(16): 1489–1499. Dostupné z DOI: <http://dx.doi.org10.1056/NEJMoa1501031>.
33. Dukát A, Kriška M. Nový prístup v liečbe hyperlipoproteinémií pomocou monoklonálnych protilátok proti proproteínkonvertáze subtilizín/kexín 9 (PCSK9). Int Med 2015; 15(19): 441–443.
34. Franeková J, Jabor A. Markery kardiovaskulárního rizika a jejich použití v běžné, neselektované populaci pacientů. Hypertenze a kardiovaskulární prevence 2012; 1(2): 37–42.
35. Vaverková H, Karásek D. Fosfolipáza A2 asociovaná s lipoproteiny (Lp-PLA2) jako ukazatel aktivity aterosklerózy a potenciální terapeutický cíl. Cor Vasa 2011; 53(4–5): 234–238.
36. Thompson A, Gao P, Orfei L et al. [Lp-PLA2 Studies Collaboration]. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375(9725): 1536–1544. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60319–4>.
37. Ballanthyne CM, Hoogeveen RC, Bang H, et al. Lp-PLA2, high-sensitivity CRP protein, an risk for incident ischemic stroke in middle-aged men and women in ARIC Study. Arch Intern Med 2005; 165(21): 2479–2484.
38. Tsai AK, Steffen BT, Ordovas JM et al. Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res 2011; 158(2): 99–105. Dostupné z DOI: <http://dx.doi.org/10.1016/j.trsl.2011.01.014>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2016 Číslo 3
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Arterin® – doplněk stravy v léčbě dyslipidemie: výsledky krátkodobého klinického sledování
- Atherogenic dyslipidemia – a new target in cardiovascular prevention
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
- Peripheral arterial disease (PAD) of lower extremity and dyslipidemia